• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Geron Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket

    1/5/23 8:01:52 AM ET
    $AMTD
    $ARBK
    $ARCK
    $CRKN
    Finance: Consumer Services
    Finance
    Finance: Consumer Services
    Finance
    Get the next $AMTD alert in real time by email

    Gainers

    • Vyant Bio, Inc. (NASDAQ:VYNT) shares rose 110.4% to $1.62 in pre-market trading after the company said it has engaged LifeSci Capital as its advisor to explore strategic alternatives.
    • Humanigen, Inc. (NASDAQ:HGEN) rose 42% to $0.24 in pre-market trading after jumping around 42% on Wednesday.
    • Oblong, Inc. (NASDAQ:OBLG) shares rose 40.7% to $3.11 in pre-market trading after gaining over 26% on Wednesday. Oblong announced a 1-for-15 reverse stock split.
    • Argo Blockchain plc (NASDAQ:ARBK) rose 37.4% to $1.65 in pre-market trading. Roth Capital, on Wednesday, upgraded Argo Blockchain from Sell to Neutral and raised the price target from $0.25 to $1.
    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) rose 23.2% to $0.3651 in pre-market trading. Crown Electrokinetics shares jumped 58% on Wednesday after the company announced it acquired Amerigen 7.
    • Arbor Rapha Capital Bioholdings Corp. I (NASDAQ:ARCK) rose 23% to $14.15 in pre-market trading.
    • Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) rose 20.4% to $4.82 in pre-market trading after gaining around 18% on Wednesday. Kiora Pharmaceuticals recently completed enrollment of clinical trial evaluating KIO-201 for persistent corneal epithelial defects.
    • AMTD IDEA Group (NYSE:AMTD) shares rose 18.2% to $1.94 in pre-market trading. AMTD IDEA Group, during November, announced 1-for-2 ADS ratio change.
    • Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) rose 15.5% to $0.1271 in pre-market trading.
    • JanOne Inc. (NASDAQ:JAN) rose 14.4% to $1.74 in pre-market trading. JanOne said effective as of December 28, 2022, the company acquired Soin Therapeutics.


    Losers

    • Vivos Therapeutics, Inc. (NASDAQ:VVOS) fell 17.5% to $1.55 in pre-market trading. Vivos Therapeutics shares jumped 154% on Wednesday after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.
    • Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares fell 16% to $0.2436 in pre-market trading after dropping over 6% on Wednesday. Dermata Therapeutics recently requested to withdraw its registration on Form S-1 and said it does not intend to pursue the contemplated public offering.
    • Nuwellis, Inc. (NASDAQ:NUWE) fell 14.3% to $9.38 in pre-market trading. Nuwellis announced passage of warrant proposal.
    • Geron Corporation (NASDAQ:GERN) shares fell 12.9% to $2.78 in pre-market trading after the company announced a proposed public offering.
    • Jasper Therapeutics, Inc. (NASDAQ:JSPR) fell 10.3% to $1.92 in pre-market trading after dropping 22% on Wednesday. Jasper Therapeutics announced European Union Orphan Drug Designation for Briquilimab as a conditioning treatment for patients prior to receiving a stem cell transplant.
    • InMed Pharmaceuticals Inc. (NASDAQ:INM) fell 10.1% to $1.96 in pre-market trading. InMed, last month, announced appointment of interim Chief Financial Officer and change of auditor.
    • Atlis Motor Vehicles, Inc. (NASDAQ:AMV) fell 9.5% to $3.30 in pre-market trading. Altis Motor Vehicles filed for offering of up to 20.46 million shares of class A common stock by selling stockholders.
    • Cryptyde, Inc. (NASDAQ:TYDE) fell 9.2% to $0.3175 in pre-market trading after jumping 81% on Wednesday. Cryptyde announced 2023 corporate priorities for the next 12 months.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) fell 9% to $4.45 in pre-market trading after jumping 25% on Wednesday. TC BioPharm, last month, posted 1H EPS of $1.13.
    • Plus Therapeutics, Inc. (NASDAQ:PSTV) fell 6.9% to $0.31 in pre-market trading after gaining over 4% on Wednesday.
    Get the next $AMTD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMTD
    $ARBK
    $ARCK
    $CRKN

    CompanyDatePrice TargetRatingAnalyst
    Janus Living Inc.
    $JAN
    4/14/2026$28.00Sector Outperform
    Scotiabank
    Janus Living Inc.
    $JAN
    4/14/2026$28.00Overweight
    KeyBanc Capital Markets
    Janus Living Inc.
    $JAN
    4/14/2026$26.00Overweight
    Barclays
    Janus Living Inc.
    $JAN
    4/14/2026$28.00Overweight
    Morgan Stanley
    Janus Living Inc.
    $JAN
    4/14/2026$27.00Outperform
    RBC Capital Mkts
    Janus Living Inc.
    $JAN
    4/14/2026$26.00Overweight
    Analyst
    Janus Living Inc.
    $JAN
    4/14/2026$27.00Overweight
    Wells Fargo
    Janus Living Inc.
    $JAN
    4/14/2026$29.00Buy
    BofA Securities
    More analyst ratings

    $AMTD
    $ARBK
    $ARCK
    $CRKN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat

    MINNEAPOLIS, April 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will participate in the AATS 106th Annual Meeting taking place May 2–5 in Chicago. The Company will be showcasing its Aquadex SmartFlow® ultrafiltration system for fluid removal at Booth 530. At the start of the event, Nuwellis will attend the ERAS Cardiac Spring Retreat gathering of thought leaders, to discuss best practices and innovation in cardiac surgery care. "AATS is one of the largest congresses in the cardiothoracic arena, and a unique opportunity to showcase our Aquadex technology, and

    4/23/26 8:30:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

    HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in support of late-stage clinical manufacturing of Rhenium-186 and REYOBIQ. With SpectronRx serving as a second GMP manufacturing site alongside Radiomedix, and Rhenium-186 isotope supplied through Telix Pharmaceuticals, Plus strengthens the reliability of its multi-partner supply chain

    4/23/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that it has granted inducement awards to Eric J Daniels, M.D., its new Chief Development Officer who joined the Company on April 20, 2026. The awards were granted on April 20, 2026 under the Company's 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist of options to purchase 20,000 shares of the Company common

    4/22/26 4:30:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $AMTD
    $ARBK
    $ARCK
    $CRKN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Janus Living with a new price target

    Scotiabank initiated coverage of Janus Living with a rating of Sector Outperform and set a new price target of $28.00

    4/14/26 9:26:51 AM ET
    $JAN
    Real Estate Investment Trusts
    Real Estate

    KeyBanc Capital Markets initiated coverage on Janus Living with a new price target

    KeyBanc Capital Markets initiated coverage of Janus Living with a rating of Overweight and set a new price target of $28.00

    4/14/26 9:26:51 AM ET
    $JAN
    Real Estate Investment Trusts
    Real Estate

    Barclays initiated coverage on Janus Living with a new price target

    Barclays initiated coverage of Janus Living with a rating of Overweight and set a new price target of $26.00

    4/14/26 8:23:16 AM ET
    $JAN
    Real Estate Investment Trusts
    Real Estate

    $AMTD
    $ARBK
    $ARCK
    $CRKN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    FDA Approval for RYTELO issued to GERON CORP

    Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

    6/7/24 12:36:59 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTD
    $ARBK
    $ARCK
    $CRKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Daniels Eric Joseph

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    4/22/26 5:00:04 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Daniels Eric Joseph

    3 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    4/21/26 5:00:06 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Williams Timothy

    4 - GERON CORP (0000886744) (Issuer)

    4/14/26 8:14:14 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTD
    $ARBK
    $ARCK
    $CRKN
    SEC Filings

    View All

    Nuwellis Inc. filed SEC Form 8-K: Other Events

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    4/24/26 5:00:23 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vivos Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    4/22/26 4:25:18 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    4/22/26 4:19:45 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTD
    $ARBK
    $ARCK
    $CRKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Holst Peter bought $9,500 worth of shares (5,000 units at $1.90), increasing direct ownership by 47% to 15,544 units (SEC Form 4)

    4 - Oblong, Inc. (0000746210) (Issuer)

    11/19/25 3:15:50 PM ET
    $OBLG
    Computer Software: Programming Data Processing
    Technology

    President and CEO Holst Peter bought $18,400 worth of shares (10,000 units at $1.84), increasing direct ownership by 1,838% to 10,544 units (SEC Form 4)

    4 - Oblong, Inc. (0000746210) (Issuer)

    11/17/25 1:12:26 PM ET
    $OBLG
    Computer Software: Programming Data Processing
    Technology

    $AMTD
    $ARBK
    $ARCK
    $CRKN
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

    HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in support of late-stage clinical manufacturing of Rhenium-186 and REYOBIQ. With SpectronRx serving as a second GMP manufacturing site alongside Radiomedix, and Rhenium-186 isotope supplied through Telix Pharmaceuticals, Plus strengthens the reliability of its multi-partner supply chain

    4/23/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

    FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.com. About GeronGero

    4/22/26 7:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vivos Therapeutics Reports Full Year 2025 Financial Results

    Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), today reported financial results and operating highlights for the full year ended December 31, 2025. Full Year 2025 Financial and Operating Summary R

    4/15/26 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $AMTD
    $ARBK
    $ARCK
    $CRKN
    Leadership Updates

    Live Leadership Updates

    View All

    Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that it has granted inducement awards to Eric J Daniels, M.D., its new Chief Development Officer who joined the Company on April 20, 2026. The awards were granted on April 20, 2026 under the Company's 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist of options to purchase 20,000 shares of the Company common

    4/22/26 4:30:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

    HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of Randy H. Goodman, Ph.D., M.H.A., as Vice President, Value Strategy & Health Economics and Outcomes Research (HEOR), effective April 13th, 2026. Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling across the biotechnology, pharmaceutic

    4/15/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary

    FOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. "Tim has deep expertise in the biopharmaceutical industry and a proven track record of leading the legal function at commercial-stage organizations," said Harout Semerjian, President and Chief Executive Officer of Geron. "The addition of Tim, coupled with our recent Board appointments, further strengthens our leadership team. His strategic counsel will be invaluable as we

    4/13/26 8:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTD
    $ARBK
    $ARCK
    $CRKN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AMTD IDEA Group

    SC 13G/A - AMTD IDEA GROUP (0001769731) (Subject)

    11/14/24 9:37:44 PM ET
    $AMTD
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

    SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 7:17:24 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 6:01:49 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care